(0.14%) 5 246.25 points
(0.16%) 39 598 points
(0.14%) 18 240 points
(0.82%) $79.91
(1.09%) $2.33
(1.35%) $2 371.80
(1.55%) $28.81
(0.71%) $997.80
(0.08%) $0.928
(-0.20%) $10.84
(-0.09%) $0.798
(-0.53%) $92.05
Live Chart Being Loaded With Signals
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally...
Stats | |
---|---|
今日成交量 | 705 131 |
平均成交量 | 969 356 |
市值 | 222.78M |
EPS | $0 ( 2024-05-09 ) |
下一个收益日期 | ( $-0.0400 ) 2024-06-11 |
Last Dividend | $0.0800 ( 2003-12-15 ) |
Next Dividend | $0 ( N/A ) |
P/E | -9.83 |
ATR14 | $0.00500 (0.43%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-07 | Culley Brian M | Buy | 1 900 000 | Employee Stock Option (Right to Buy) |
2024-03-07 | Samuel George A. Iii | Buy | 650 000 | Employee Stock Option (Right to Buy) |
2024-03-07 | Howe Jill Ann | Buy | 650 000 | Employee Stock Option (Right to Buy) |
2024-02-11 | Samuel George A. Iii | Sell | 6 076 | Restricted Stock Units |
2024-02-11 | Samuel George A. Iii | Buy | 6 076 | Common Shares, no par value |
INSIDER POWER |
---|
98.19 |
Last 93 transactions |
Buy: 20 710 358 | Sell: 1 476 683 |
音量 相关性
Lineage Cell Therapeutics 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Lineage Cell Therapeutics 相关性 - 货币/商品
Lineage Cell Therapeutics 财务报表
Annual | 2023 |
营收: | $8.95M |
毛利润: | $7.58M (84.76 %) |
EPS: | $-0.120 |
FY | 2023 |
营收: | $8.95M |
毛利润: | $7.58M (84.76 %) |
EPS: | $-0.120 |
FY | 2022 |
营收: | $14.70M |
毛利润: | $13.98M (95.05 %) |
EPS: | $-0.160 |
FY | 2021 |
营收: | $3.90M |
毛利润: | $2.47M (63.40 %) |
EPS: | $-0.260 |
Financial Reports:
No articles found.
Lineage Cell Therapeutics Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0800 | 2003-12-15 |
Last Dividend | $0.0800 | 2003-12-15 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.0800 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PRK | Ex Dividend Knight | 2023-08-17 | Quarterly | 0 | 0.00% | |
DFUS | Ex Dividend Junior | 2023-09-19 | Quarterly | 0 | 0.00% | |
IHT | Ex Dividend Knight | 2023-07-19 | Semi-Annually | 0 | 0.00% | |
NTIP | Ex Dividend Junior | 2023-09-18 | Semi-Annually | 0 | 0.00% | |
CQP | Ex Dividend Knight | 2023-08-04 | Quarterly | 0 | 0.00% | |
GLV | Ex Dividend Knight | 2023-09-21 | Monthly | 0 | 0.00% | |
NEN | Ex Dividend Knight | 2023-09-14 | Quarterly | 0 | 0.00% | |
WTV | Ex Dividend Junior | 2023-06-26 | Quarterly | 0 | 0.00% | |
CET | Ex Dividend Knight | 2023-06-09 | Semi-Annually | 0 | 0.00% | |
FRD | Ex Dividend Knight | 2023-10-19 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -2.41 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.213 | 1.200 | -7.10 | -8.52 | [0 - 0.3] |
returnOnEquityTTM | -0.313 | 1.500 | -4.59 | -6.89 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.14 | 0.800 | 4.30 | 3.44 | [1 - 3] |
quickRatioTTM | 2.02 | 0.800 | 2.84 | 2.27 | [0.8 - 2.5] |
cashRatioTTM | 1.973 | 1.500 | 0.148 | 0.222 | [0.2 - 2] |
debtRatioTTM | 0.0292 | -1.500 | 9.51 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 56.86 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.165 | 2.00 | -0.0551 | -0.110 | [0 - 30] |
freeCashFlowPerShareTTM | -0.169 | 2.00 | -0.0847 | -0.169 | [0 - 20] |
debtEquityRatioTTM | 0.0465 | -1.500 | 9.81 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.905 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -2.77 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -9.68 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0885 | 0.800 | -2.74 | -2.19 | [0.5 - 2] |
Total Score | -0.295 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -9.31 | 1.000 | -1.041 | 0 | [1 - 100] |
returnOnEquityTTM | -0.313 | 2.50 | -2.95 | -6.89 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.169 | 2.00 | -0.0564 | -0.169 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.165 | 2.00 | -0.0551 | -0.110 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0603 | 1.500 | -2.93 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -3.19 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.30 |
Lineage Cell Therapeutics
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。